Top

Published in:

01-02-2013 | Research Article

Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma

Authors: Ze-Kun Zhao, Ping Dong, Jun Gu, Lei Chen, Ming Zhuang, Wen-Jie Lu, Dao-Rong Wang, Ying-Bin Liu

Published in: Tumor Biology | Issue 1/2013

Abstract

The aim of this study was to investigate the expression of LSD1 in human hepatocellular carcinoma (HCC) cell lines and HCC samples. In this study, we examined LSD1 expression in 60 paired liver cancer tissues and adjacent noncancerous tissues by Western blot. In addition, we analyzed LSD1 expression in 198 HCC samples by immunohistochemistry. The relationship between LSD1 expression and clinicopathological features was investigated. The HCC cell line SMMC-7721 was transfected with LSD1 siRNA expressing plasmids. We subsequently examined in vitro cell growth using the MTT assay and anchorage-independent growth through a soft-agar colony-formation assay. In addition, the expression levels of Bcl-2 and c-Myc were also examined. Immunohistochemistry and Western blotting consistently confirmed LSD1 overexpression in HCC tissues compared with adjacent non-neoplastic tissues (P < 0.01). Additionally, immunostaining showed more LSD1-positive cells in the higher tumor stage (T3–4) and tumor grade (G3) than in the lower tumor stage (T1–2, P < 0.001) and tumor grade (G1–2, P < 0.001). Knockdown of LSD1 expression in HCC cells led to decreased cell proliferation. The expression of Bcl-2 and c-Myc were down-regulated after transfection of LSD1 siRNA into HCC cell line SMMC-7721. In conclusion, because LSD1 was overexpressed in HCC and has an important role in the development of HCC, LSD1 could be a latent target in the diagnosis and therapy of HCC.

Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. Dig Dis. 2009;27:80–92. doi:10.1159/000218339.PubMed

Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15–9. doi:10.1016/S0009-8981(01)00644-1.PubMedCrossRef

Blum HE, Spangenberg HC. Hepatocellular carcinoma: an update. Arch Iran Med. 2007;10:361–71.PubMed

Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature. 2007;446:882–7. doi:10.1038/nature05671.PubMedCrossRef

Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem. 2007;282:15471–5. doi:10.1074/jbc.M701023200.PubMedCrossRef

Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010;31:512–20. doi:10.1093/carcin/bgp324.PubMedCrossRef

Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, Tsunoda T, et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011;128:574–86. doi:10.1002/ijc.25349.PubMedCrossRef

Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One. 2007;2:e534. doi:10.1371/journal.pone.0000534.PubMedCrossRef

Guo X, Xiong L, Zou L, Zhao J. Upregulation of bone morphogenetic protein 4 is associated with poor prognosis in patients with hepatocellular carcinoma. Pathol Oncol Res. 2012;18:635–40. doi:10.1007/s12253-011-9488-2.PubMedCrossRef

10.

Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol. 2011;6:121. doi:10.1186/1746-1596-6-121.PubMedCrossRef

11.

Hong H, Patonay B, Finley J. Unusual reticulin staining pattern in well-differentiated hepatocellular carcinoma. Diagn Pathol. 2011;6:15. doi:10.1186/1746-1596-6-15.PubMedCrossRef

12.

Müller P, Crofts JD, Newman BS, Bridgewater LC, Lin CY, Gustafsson JA, et al. SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat. 2010;120:317–26. doi:10.1007/s10549-009-0381-6.PubMedCrossRef

13.

Lü B, Fang Y, Xu J, Wang L, Xu F, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008;130:897–904. doi:10.1309/AJCPW1W8GJBQGCNI.PubMedCrossRef

14.

Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576–85. doi:10.1002/cncr.24495.PubMedCrossRef

15.

Piperi C, Vlastos F, Farmaki E, Martinet N, Papavassiliou AG. Epigenetic effects of lung cancer predisposing factors impact on clinical diagnosis and prognosis. J Cell Mol Med. 2008;12:1495–501.PubMedCrossRef

16.

Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol. 2009;174:1619–28. doi:10.2353/ajpath.2009.080874.PubMedCrossRef

17.

Yang S. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet. 2007;8:829–33. doi:10.1038/nrg2218.CrossRef

18.

Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer. 2008;123:1–7. doi:10.1002/ijc.23605.PubMedCrossRef

19.

Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, et al. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc. 2009;131:17536–7. doi:10.1021/ja907055q.PubMedCrossRef

20.

Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53. doi:10.1016/j.cell.2004.12.012.PubMedCrossRef

21.

Lim S, Metzger E, Schüle R, Kirfel J, Buettner R. Epigenetic regulation of cancer growth by histone demethylases. Int J Cancer. 2010;127:1991–8. doi:10.1002/ijc.25538.PubMedCrossRef

22.

Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009;69:2065–71. doi:10.1158/0008-5472.CAN-08-1735.PubMedCrossRef

23.

Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate. 2010;70:889–98. doi:10.1002/pros.21123.PubMed

24.

Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 2012;7:e35065. doi:10.1371/journal.pone.0035065.PubMedCrossRef

25.

Brunelle JK, Santore MT, Budinger GR, Tang Y, Barrett TA, Zong WX, et al. c-Myc sensitization to oxygen deprivation-induced cell death is dependent on Bax/Bak, but is independent of p53 and hypoxia inducible factor-1. J Biol Chem. 2004;279:4305–12. doi:10.1074/jbc.M312241200.PubMedCrossRef

26.

Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005;25:1608–19. doi:10.1128/MCB.25.5.1608-1619.2005.PubMedCrossRef

27.

Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, Höpfner M, et al. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol. 2004;41:799–807.PubMedCrossRef

Title: Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma
Authors: Ze-Kun Zhao
Ping Dong
Jun Gu
Lei Chen
Ming Zhuang
Wen-Jie Lu
Dao-Rong Wang
Ying-Bin Liu
Publication date: 01-02-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 1/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0525-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

RETRACTED ARTICLE: The interaction between smoking and GSTM1 variant on lung cancer in the Chinese population

EphB4 is overexpressed in gliomas and promotes the growth of glioma cells

Association of human herpes, papilloma and polyoma virus families with bladder cancer

No significant association between p53 codon 72 Arg/Pro polymorphism and risk of oral cancer

Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand

MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer